Partnership to Close the Data Gap Between Blood Collection and Lab Analysis
Global clinical diagnostics company, Beckman Coulter, has
announced a new partnership with Germany-based company, Smart4Diagnostics, to close the preanalytical data gap between blood collection and laboratory analysis due to errors that take place before the sample arrives in the laboratory, such as sample collection, patient identifi cation, sample handling, sample transportation, sample loss, etc.
Clinical laboratories are well aware of the pain points encountered in the preanalytical phase of the sample journey, which is when the vast majority of errors take place. These include patient identifi cation and sample collection, handling, and transportation. Up to 75% of the errors in the preanalytical phase take place outside of the lab, meaning that laboratories have very little, if any, control over this part of the process.
“Beckman Coulter has been automating and digitising medical laboratories throughout the world for over 40 years, and has now turned its attention to digitising the part of the preanalytical phase that happens outside of the laboratory. Thanks to the partnership with Smart4Diagnostics, Beckman Coulter will be able to monitor not only what happens inside the laboratory but the entire sample process, fi lling the existing gap between sample collection and clinical laboratories,” said Tom Coulson, EU Senior Manager for Workfl ow & IT Solutions.
Requesting that patients provide new samples due to these errors may result in patient discomfort, reduced trust and, most notably, delayed treatments. Whereas for laboratories, errors mean extra work, increased operating costs and decreased productivity. Smart4Diagnostics created a data-driven preanalytical ecosystem. From sample ordering to sample arrival, Smart4Diagnostics collects all relevant data-points to completely monitor sample workfl ow and conditions. By doing so, it is able to reduce preanalytical errors in real time while also improving the preanalytical workfl ow and quality of treatment.
Beckman Coulter has partnered with Smart4Diagnostics to close the preanalytical data gap between blood collection and laboratory analysis.
According to Dr Hans Maria Heyn, CEO & Co-Founder of Smart4Diagnostics: “As many as three in four medical decisions are based on diagnostic results – often blood samples. Currently, the fi rst part of this process is being managed manually, which can lead to errors and cause issues, including slow diagnosis, repeated tests on the patient, and wasted resources. This partnership with Beckman Coulter seeks to revolutionise this crucial but underdeveloped area of the healthcare value chain to bring innovation where it can have an instant and substantial impact.”
More information online:
ilmt.co/PL/zOlL 58185pr@reply-direct.com
New Lab Facilities extends OOC Contract Research Capabilities
NEQAS Sets Stage for New UK Division
Molecular diagnostics products manufacturer HiberGene Diagnostics is to supply its point-of-care (POC) and near-patient testing solutions directly to healthcare providers in the UK and Ireland.
The Dublin-based company’s test solutions which cover infectious and transmissible disease areas - including respiratory, sexually transmitted infections, hospital acquired infections and women’s health – have been designed for improved turnaround in result times in almost any setting, bringing cost and time savings along with improved patient management.
Complementing the opening of its UK division, HiberGene were sponsors of UK NEQAS’ multi-disciplinary event ‘Supporting your point of care testing (POCT) service’ held at the Hyatt Regency Hotel in Birmingham on 30 June 2022. At the one-day seminar the company took part in key discussions on accrediting and implementing these services in a healthcare setting and the benefi ts that this can bring for both patients and clinicians.
CN Bio’s expanded lab facilities at Cambridge Science Park
Organ-on-a-chip (OOC) company CN Bio a designer and manufacturer of single-and multi-organ microphysiological systems (MPS), has announced the opening of new laboratory facilities at Cambridge Science Park. This move has doubled the company’s laboratory space as a response to the increasing market demand for OOC services as its MPS technology gains traction within drug discovery and development programmes. Using generated data for its customers, the team collaborates with researchers to create an experimental design that delivers unique human-translatable insights, whilst saving signifi cant time and cost versus animal studies.
The rising demand for these services demonstrates acceptance of OOC data by pharma and biotech companies in their therapeutic programmes. This is being fuelled by repeat business, growing interest from regulatory agencies, the technology’s ability to predict clinical outcomes and its potential to replace animal models - especially for the testing of new drug modalities with human-specifi c modes of action.
Dr Gareth Guenigault, Lead Scientist of CN Bio’s Contract Research Services, said: “This expansion is an exciting next step in the progression of our contract research services offering. As we see increasing awareness within the drug discovery, development and regulatory fi elds that animal models don’t always get it right, nor are ethically desirable, we are poised to offer solutions that fi t researchers’ individual needs. By utilising the power of OOC technology to provide early stage, clinically translatable data across a range of applications, we hope to give customers greater confi dence in the success of their projects, in a fraction of the time and cost.”
More information online:
ilmt.co/PL/Y09Y 58291pr@reply-direct.com
David Corr CEO of HiberGene said: “After immense success in Ireland, we are excited to announce the launch of our new, dedicated UK team, increasing our geographical reach and capabilities for our growing customer base. Our multi-disciplinary teams possess deep
David Corr
technical knowledge on a wide variety of testing options to deliver the best solution for each customer enjoyed showcasing their knowledge in key discussions at the UK NEQAS event.”
More information online:
ilmt.co/PL/E2O6 58213pr@reply-direct.com
UK Study aims to set new NHS Healthcare Guidance
Our Future Health, the UK’s largest ever health research programme, has selected UK Biocentre to process and store up to 50 million samples collected from adults across the UK which will support vital research aiming to discover and develop new methods of early detection and treatment of diseases such as cancer, dementia, heart disease, arthritis, diabetes and stroke.
Recruiting up to fi ve million UK adults to create a detailed picture that truly refl ects the population, the research aims to pave the way for a bold new approach to healthcare in the NHS, focused on detecting life-changing conditions before symptoms appear, leading to better treatment outcomes and people living longer, healthier lives.
A world leader in sample processing UK Biocentre’s purpose- built laboratories in Milton Keynes will use the latest automated technologies to:
• Receive and process up to 10,000 blood samples per day
• Process fresh blood samples to constituent aliquots for future biological analysis • Extract DNA from blood samples for future genetic analysis
• Store up to 50 million aliquoted blood samples in fully automated storage systems at -80°C for future research use. Andrew Roddam, CEO of Our Future Health, said: “We’re delighted
that UK Biocentre will be one of our key partners supporting us in the processing of our participants’ blood samples and be solely responsible for the long-term ultra-low temperature sample storage. Their wealth of experience will ensure our volunteers’ samples are in good hands.”
Dr Tony Cox OBE, CEO at UK Biocentre, said: “We are delighted to support Our Future Health, a ground-breaking research programme, which will lead to more of us living healthier lives for longer. Our strong track record, expertise and scale mean we can process and store the 50 million samples from the volunteers who take part in the Our Future Health study. We look forward to playing our part and working with all partners involved on this nationally signifi cant programme.”
UK Biocentre has a successful track record in high-capacity processing and storing samples. Its staff of 800 supported the nation’s response to the COVID-19 pandemic by testing more than 30 million samples. It stores samples for more than a hundred organisations including the Government, academic institutions, the NHS, and other research partners.
More information online:
ilmt.co/PL/Wxgn 58159pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
